SCHEMBL734584

SCHEMBL734584

CC1C(=O)NCCN1c1cccc(C(F)(F)F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 2/20 0.49
ALDH1A1 P00352 2/20 0.49
HTR3E A5X5Y0 1/20 0.49
HTR3B O95264 1/20 0.49
HTR1D P28221 1/20 0.49
HTR3A P46098 1/20 0.49
HTR3D Q70Z44 1/20 0.49
HTR3C Q8WXA8 1/20 0.49
SIGMAR1 Q99720 1/20 0.49
MAPT P10636 2/20 0.48
THRB P10828 1/20 0.48
HTR2A P28223 1/20 0.47
HTR2B P41595 1/20 0.47
ALOX5 P09917 1/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
AR P10275 1/20 0.44
HTR7 P34969 1/20 0.44
CYP1A2 P05177 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13934666 0.86 HTR2C (0.46) HTR2CALDH1A1HTR3EHTR3BHTR1D
SCHEMBL734450 0.82 NOTUM (0.44) BCL2A1
SCHEMBL735198 0.77 BCL2A1 (0.43) HTR2CHTR2AHTR2BARBCL2A1
SCHEMBL734459 0.77 BCL2A1 (0.54) HTR2CHTR2AHTR2BMEN1KMT2A
SCHEMBL5631654 0.76 HTR2C (0.58) HTR2CALDH1A1HTR3EHTR3BHTR1D
SCHEMBL5632538 0.76 HTR2C (0.58) HTR2CALDH1A1HTR3EHTR3BHTR1D
SCHEMBL5632981 0.76 HTR2C (0.58) HTR2CALDH1A1HTR3EHTR3BHTR1D
SCHEMBL1845527 0.75 HTR2C (0.44) HTR2CALDH1A1HTR3EHTR3BHTR1D
Hydrochloric Acid SCHEMBL5630520 0.75 MAPT (0.59) HTR2CALDH1A1HTR3EHTR3BHTR1D
Hydrochloric Acid SCHEMBL5631586 0.75 MAPT (0.59) HTR2CALDH1A1HTR3EHTR3BHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US disclosed
EP-2321285-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-La Roche AG (CH) 2011-05-18 EP disclosed
WO-2010012619-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 WO disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 HTR2C 623/4885ALDH1A1 2750/4885HTR3E 244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.